Cardiovascular Risk Stratification in Covid-19

Completed

• Conditions: Covid19; Cardiovascular Risk Factor

• Registration Number: NCT04555187
• Lead Sponsor: Oregon Health and Science University

Brief Summary

This retrospective double-cohort study seeks to:

1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and

2. Develop a method of cardiovascular risk stratification in COVID-19

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-08
• Study First Submitted: 2020-09-16
• Study First Submitted QC: 2020-09-16
• Study First Posted: 2020-09-18
• Primary Completion: 2021-12-01
• Study Completion: 2021-12-01
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-05
• Last Update Posted: 2023-11-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1355

Inclusion Criteria

• age >=18y
• available data on Covid19 test in the electronic medical record (either positive or negative)

Exclusion Criteria

• no data of Covid19 test

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number and rate of persons with cardiovascular composite outcome	6 months after Covid19 test	Number and rate of persons with composite of all-cause death, critical care utilization (ICU bed), development of a life-threatening arrhythmia (ventricular tachycardia/ventricular fibrillation or sudden cardiac arrest), acute heart failure, myocardial infarction (STEMI, NSTEMI, or silent MI), or incident stroke, whichever comes first.

Secondary Outcome Measures

Name	Time	Method
Rate of all-cause death outcome	6 months after covid19 test	Rate of all-cause death outcome
Rate of cardiac arrhythmia	6 months after covid19 test	Rate of any documented cardiac arrhythmia (tachy - or brady- arrhythmia)

Trial Locations

Locations (1)

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States